Work

Crizotinib-induced hyperlipidemia in advanced lung adenocarcinoma: A case report and literature review

Year: 2026

Type: article

Abstract: RATIONALE: Crizotinib is a multi-target small molecule tyrosine kinase inhibitor that specifically targets anaplastic lymphoma kinase, mesenchymal-epithelial transition factor/hepatocyte growth factor receptor, and c-ROS oncogene 1 (ROS1). Its primary application in clinical settings is for the treatment of advanced non-small-cell lung cancer characterized by anaplastic lymphoma kinase-positive and/or ROS1 fusion gene-positive status. Hyperlipidemia is a rarely documented adverse reaction to crizotinib, with its underlying mechanisms and clinical management strategies remaining unclear. PATIENT CONCERNS: Significant dyslipidemia was observed in a 70-year-old female with advanced, ROS1 fusion-positive lung adenocarcinoma during crizotinib therapy. DIAGNOSES: This case report presents a patient diagnosed with advanced lung adenocarcinoma harboring an ROS1 fusion gene, who subsequently developed severe hyperlipidemia during treatment with the targeted agent crizotinib. INTERVENTIONS: A combined strategy of crizotinib dose reduction and concomitant lipid-lowering therapy was initiated to address the hyperlipidemia, aiming to maintain control of the primary malignancy while managing the adverse effect. OUTCOMES: Following a reduction in the dosage of crizotinib and the implementation of proactive lipid-lowering interventions, both the malignancy and the associated adverse effects were effectively controlled. LESSONS: The condition exhibited a typical positive rechallenge feature of "discontinuation and recurrence," providing critical clinical evidence to establish this causal relationship. The case aims to enhance the understanding of crizotinib's metabolic side effects, underscores the importance of dynamic lipid monitoring, and offers empirical support for the standardized management of such rare adverse reactions.

Source: Medicine

DOI: 10.1097/md.0000000000047276

Authors: Shuai Ren, Ruifang Chen

Institution: Shanghai Public Health Clinical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,950